Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
- PMID: 24996814
- PMCID: PMC4105891
- DOI: 10.1186/1750-1172-9-99
Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe
Abstract
Background: Hereditary angioedema (HAE) due to C1 inhibitor deficiency is a rare but serious and potentially life-threatening disease marked by spontaneous, recurrent attacks of swelling. The study objective was to characterize direct and indirect resource utilization associated with HAE from the patient perspective in Europe.
Methods: The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months. A regression model examined predictors of medical resource utilization.
Results: Overall, 164 patients had an attack in the past 6 months and were included in the analysis. The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001). Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department. The last attack prevented patients from their normal activities an average of 4-12 hours. Patient and caregiver absenteeism increased with attack severity and frequency. Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.
Conclusion: HAE poses a considerable burden on patients and their families in terms of direct medical costs and indirect costs related to lost productivity. This burden is substantial at the time of attacks and in between attacks.
Figures




Similar articles
-
The humanistic burden of hereditary angioedema: results from the Burden of Illness Study in Europe.Allergy Asthma Proc. 2014 Jan-Feb;35(1):47-53. doi: 10.2500/aap.2013.34.3685. Epub 2013 Nov 22. Allergy Asthma Proc. 2014. PMID: 24268449
-
Economic costs associated with acute attacks and long-term management of hereditary angioedema.Ann Allergy Asthma Immunol. 2010 Apr;104(4):314-20. doi: 10.1016/j.anai.2010.01.024. Ann Allergy Asthma Immunol. 2010. PMID: 20408341
-
The hereditary angioedema burden of illness study in Europe (HAE-BOIS-Europe): background and methodology.BMC Dermatol. 2012 Apr 26;12:4. doi: 10.1186/1471-5945-12-4. BMC Dermatol. 2012. PMID: 22536794 Free PMC article.
-
Hereditary angioedema: Epidemiology and burden of disease.Allergy Asthma Proc. 2020 Nov 1;41(Suppl 1):S08-S13. doi: 10.2500/aap.2020.41.200050. Allergy Asthma Proc. 2020. PMID: 33109318 Review.
-
The burden of illness in patients with hereditary angioedema.Ann Allergy Asthma Immunol. 2013 Nov;111(5):329-36. doi: 10.1016/j.anai.2013.08.019. Epub 2013 Sep 18. Ann Allergy Asthma Immunol. 2013. PMID: 24125136 Review.
Cited by
-
Assessment and management of disease burden and quality of life in patients with hereditary angioedema: a consensus report.Allergy Asthma Clin Immunol. 2021 Apr 19;17(1):40. doi: 10.1186/s13223-021-00537-2. Allergy Asthma Clin Immunol. 2021. PMID: 33875020 Free PMC article. Review.
-
Training patients for self-administration of a new subcutaneous C1-inhibitor concentrate for hereditary angioedema.Nurs Open. 2018 Aug 28;6(1):126-135. doi: 10.1002/nop2.194. eCollection 2019 Jan. Nurs Open. 2018. PMID: 30534402 Free PMC article.
-
The Humanistic, Societal, and Pharmaco-economic Burden of Angioedema.Clin Rev Allergy Immunol. 2016 Oct;51(2):230-9. doi: 10.1007/s12016-016-8575-2. Clin Rev Allergy Immunol. 2016. PMID: 27388236 Review.
-
Disease Severity, Activity, Impact, and Control and How to Assess Them in Patients with Hereditary Angioedema.Front Med (Lausanne). 2017 Dec 4;4:212. doi: 10.3389/fmed.2017.00212. eCollection 2017. Front Med (Lausanne). 2017. PMID: 29255709 Free PMC article. Review.
-
Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors.Pharmacoeconomics. 2017 Sep;35(9):895-908. doi: 10.1007/s40273-017-0522-4. Pharmacoeconomics. 2017. PMID: 28597368 Free PMC article.
References
-
- Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine. 1992;71:206–215. - PubMed
-
- Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med. 1976;84:580–593. - PubMed
-
- Caballero T, Baeza M, Cabanas R, Campos A, Cimbollek S, Gomez-Traseira C, Gonzalez-Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, Lopez-Serrano MC, Lopez-Trascasa M, Marcos C, Munoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin: part I: classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21:333–347. - PubMed
-
- Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med. 2006;119:267–274. - PubMed
-
- Bygum A. Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol. 2009;161:1153–1158. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous